此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

调查 ABBV-CLS-7262 在消失的白质患者中的安全性、耐受性和药代动力学的 1b 期研究

2026年10月16日 更新者:Calico Life Sciences LLC

一项 1b 期开放标签研究,以评估 ABBV-CLS-7262 对患有消失性白质病的成年受试者给药后的安全性、耐受性和药代动力学

Fosigotifator is an investigational drug being researched for the treatment of Vanishing White Matter disease in adult, pediatric and infant participants. This is a 201-week, open-label, multiple cohort study enrolling adults, pediatric and infant participants with Vanishing White Matter disease.

Participants will attend regular visits during the course of the study and complete medical assessments, blood tests, questionnaires, and be evaluated for side effects.

研究概览

地位

招聘中

研究类型

介入性

注册 (估计的)

50

阶段

  • 阶段2
  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Quebec
      • Montreal、Quebec、加拿大、H3H2L9
        • 招聘中
        • McGill University Health Centre - Glen Site
    • Massachusetts
      • Boston、Massachusetts、美国、02114
        • 招聘中
        • Massachusetts General Hospital /ID# 270960
    • Pennsylvania
      • Philadelphia、Pennsylvania、美国、19104
        • 招聘中
        • Children's Hospital of Philadelphia
    • Utah
      • Salt Lake City、Utah、美国、84112-5339
        • 招聘中
        • University of Utah /ID# 255624
    • North Holland
      • Amsterdam、North Holland、荷兰、1081 HV
        • 招聘中
        • Amsterdam UMC, locatie VUmc /ID# 270955

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

6个月 及以上 (孩子、成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Males and females ≥18 y of age (Cohort 1 and Cohort 1b - adults), ≥12 y and <18 y of age (Cohort 2 - adolescents), ≥6 y and <12 y of age (Cohort 3 - children), and ≥6 mos and <6 y of age (Cohort 4 - children [≥1 y and <6 y of age] and infants [≥6 mos and <1 y of age]) at the time of Screening.

  2. Subject must have VWM disease defined as:

    • A clinical diagnosis by a physician experienced in the assessment of VWM disease, AND
    • A molecular diagnosis of VWM disease (Note: Subjects who can provide a verified laboratory report of previously performed VWM molecular diagnosis, including the specific mutation(s), will not be required to reconfirm diagnosis before Screening), AND
    • A magnetic resonance imaging (MRI) presentation consistent with VWM disease, as assessed by a neuroradiologist or by a physician experienced in the assessment of VWM disease except for presymptomatic homozygous carriers of Cree leukoencephalopathy (EIF2B5 R195H) or other mutation with known imminent risk of significant clinical decline or death (requires approval from Sponsor).
  3. Subject must have a designated caregiver who is able to complete the respective caregiver ce ntered assessments. The caregiver must be consistently present at visits, including telehealth visits, to report on symptoms and comply with the protocol. The caregiver must be willing to provide informed consent.

  4. Subject is willing and able to give informed consent. Where local regulations permit inclusion of participants deemed not able to provide informed consent, a legally authorized representative (LAR) must provide informed consent on the subject's behalf, and the subject must provide assent, in accordance with the local regulations, guidelines, and Institutional Review Board (IRB), or Independent Ethics Committee (IEC). If the subject becomes cognitively impaired (diminished capacities) during the study and is unable to provide informed consent, the subject should be discontinued from the study unless local regulations permit inclusion of participants deemed not able to provide informed consent. In such case, a LAR must provide informed consent on behalf of the subject and the subject must provide assent as per local regulations, guidelines, and IRB or IEC. Careful consideration will be given to ensure that cognitive impairment/diminished capacity does not limit the subject's right to withdraw from the study. The LAR and the caregiver can be the same person.

  5. Subjects in Cohorts 1, 1b, 2, and 3 must meet criteria a and at least 1 of the other criteria listed below (b or c):

    • Medical history of at least 1 neurological symptom that is assessed by the investigator as having a reasonable possibility of being related to VWM disease
    • Motor criteria as defined below:

    All age groups:

    Inability to walk 10 or more steps with or without light support of 2 hands

    - Cognitive criteria as defined below (Note: Subjects are not required to complete testing if they meet the motor criteria or if they are able to provide source documentation of prior cognitive testing performed by a qualified psychologist and meeting eligibility criteria obtained in the past 12 months):

    Adults and adolescents ≥16 y of age must have:

    A perceptual reasoning index <50 (Wechsler Adult Intelligence Scale, fourth edition [WAIS-IV])

    Adolescents and children ≥6 y and <16 y of age must have:

    A visuospatial reasoning index <50 (block design, visual puzzles, Wechsler Intelligence Scale for Children performance, fifth edition [WISC-V]) AND A fluid reasoning index <50 (matrix reasoning, figure weights, WISC-V). Note: At the Sponsor's discretion, pediatric subjects <16 y of age who are unable to complete the subtests for calculating BOTH indices of the WISC-V due to functional impairment (e.g., due to fine motor or visual impairment) may meet inclusion criteria by a score <50 on either the visuospatial reasoning index OR the fluid reasoning index of the WISC-V.

    Pediatric subjects in Cohort 4 must meet both criteria a and b below, or criterion c:

    Medical history of at least 1 neurological symptom that is assessed by the investigator as having a reasonable possibility of being related to VWM disease

    Motor criteria as defined below:

    More than minimal head control as demonstrated by:

    While in prone position, the subject can lift his/her head and sustain the position for 10 seconds and bring his/her arms actively to weight bearing in that position Presymptomatic and homozygous for Cree Leukoencephalopathy (EIF2B5 R195H) or other mutation with known imminent risk of significant clinical decline or death (sponsor must be notified and provide approval prior to screening and enrolling a patient that meets eligibility with only this criterion).

  6. All male subjects who are sexually active and not surgically sterilized must agree to use an acceptable contraceptive method. Additionally, male subjects must agree to not donate sperm during the study and until 30 days after the final dose of study drug.

  7. All female subjects who are sexually active and of childbearing potential must agree to use an acceptable contraceptive method. Additionally, female subjects must agree to not donate eggs during the study and for 30 days after the final dose of study drug.

  8. Canada-specific Cohort 5: Male and female infant subjects between 0 mos and <6 mos of age at the time of Screening.

  9. Canada-specific Cohort 5: Subject body weight ≥5 kg at the time of the Baseline visit. The screening period can be extended by up to 30 days to ensure that this minimum weight is met at the Baseline visit.

  10. Canada-specific Cohort 5: Homozygous carriers of Cree leukoencephalopathy (EIF2B5 R195H) or other mutation(s) with known imminent risk of significant clinical decline or death (the Sponsor must be notified and provide approval prior to screening and enrolling a patient that meets eligibility with only this criterion).

An MRI presentation consistent with VWM disease is not required for Cohort 5. Exclusion Criteria

  1. Pediatric subjects ≥6 mos and <6 y of age must not be on any form of respiratory support at the time of Screening.
  2. Subject who has any clinically significant electrocardiogram (ECG) abnormalities, including QT interval corrected for heart rate using Fridericia's correction formula (QTcF) of >450 msec for adult males, >470 msec for adult females, or >450 msec for adolescents ≥12 y and <18 y of age (Cohort 2) and children ≥6 y and <12 y of age (Cohort 3), or >414 msec for infants and children ≥0.5 y and <6 y of age (Cohort 4).
  3. Subject with current or history of abnormal screening laboratory or imaging results that, in the opinion of the Investigator, are indicative of any significant cardiac, endocrinologic, hematologic, hepatic, immunologic, infectious, metabolic, urologic, pulmonary, gastrointestinal, dermatologic, psychiatric, renal, neurologic, and/or other major disease (other than VWM) that would preclude administration of FGT or safe participation in the study Abnormal adrenal function, defined as confirmed abnormal random cortisol or ACTH at Screening (see Section 7.2.8 for cortisol and ACTH thresholds) Participants may undergo repeat cortisol and ACTH testing once, in order to establish normal adrenal function. If repeat cortisol and/or ACTH testing is abnormal, at the Investigator's discretion, the participant may undergo cosyntropin stimulation testing to establish normal adrenal function to meet eligibility criteria.
  4. Subject who has suicidal ideation at the Screening Visit (V1). Prior medical history and/or Columbia-Suicide Severity Rating Scale (C-SSRS) may be used to inform the Investigator's decision.
  5. Changes in medication use for the management of VWM disease symptoms within the 4 weeks preceding Screening.
  6. Seizure disorder not considered adequately controlled by the Investigator within the 6 months preceding Screening.
  7. Subject who, in the opinion of the Investigator, is incapable of completing study-required visits and procedures to assess primary and secondary endpoints (e.g., due to severe comorbid conditions or severity of VWM disease).
  8. Subjects who are pregnant, breastfeeding, or providing breast milk. Note: Infant subjects are permitted to receive breast milk from a non-participant mother or caregiver (who is not receiving the study intervention).
  9. Canada-specific Cohort 5: Subjects between 0 mos and <6 mos of age must not be on any form of respiratory support at the time of Screening.
  10. Canada-specific Cohort 5: Subject who has any clinically significant ECG abnormalities, including QT interval corrected for heart rate using Fridericia's correction formula (QTcF) of >414 msec for infants between 0 mos and <6 mos of age

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:非随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Fosigotifator - Cohort 1

Cohort 1: VWM adults >= 18 years.

Oral Use

其他名称:
  • ABBV-CLS-7262
实验性的:Fosigotifator - Cohort 1b

Cohort 1b: VWM adults >= 18 years.

Oral Use

其他名称:
  • ABBV-CLS-7262
实验性的:Fosigotifator - Cohort 2

Cohort 2: VWM children>= 12 y and <18 years.

Oral Use

其他名称:
  • ABBV-CLS-7262
实验性的:Fosigotifator - Cohort 3

Cohort 3: VWM children >= 6 y and <12 years.

Oral Use

其他名称:
  • ABBV-CLS-7262
实验性的:Fosigotifator - Cohort 4

Cohort 4: VWM children >= 6 months and <6 years.

Oral Use

其他名称:
  • ABBV-CLS-7262
实验性的:Fosigotifator - Cohort 5 (Canada Only)

VWM Children >0 and <6 months

Oral Use

其他名称:
  • ABBV-CLS-7262

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Incidence of Treatment-Emergent Adverse Events
大体时间:Baseline up to Approximately Day 28

Number of participants with treatment-related adverse events as assessed by CTCAE v4.03

Baseline up to Approximately Day 28
Number of Participants with Change in Vital Signs
大体时间:Baseline up to Approximately Day 28

Number of Participants with Change in Vital Signs will be assessed.

Baseline up to Approximately Day 28
Number of Participants with Change in ECG
大体时间:Baseline up to Approximately Day 28

Number of Participants with Change in ECG will be assessed.

Baseline up to Approximately Day 28
Number of Participants with Change in Clinical Laboratory Tests
大体时间:Baseline up to Approximately Day 28

Number of participants with change in clinical laboratory tests will be assessed.

Baseline up to Approximately Day 28
Change from Baseline in Columbia-Suicide Severity Rating Scale (C-SSRS)
大体时间:Baseline up to Approximately Day 28

The C-SSRS is a systematically administered instrument that reports the severity of both suicidal ideation and behavior, with a higher score denoting more severe suicidal ideation and behavior.

Baseline up to Approximately Day 28
Plasma Concentration of Fosigotifator
大体时间:Baseline up to approximately Week 96

Maximum Plasma Concentration [Cmax]

Baseline up to approximately Week 96
Time to Cmax (Tmax) of Fosigotifator
大体时间:Baseline up to approximately Week 96

Tmax of Fosigotifator

Baseline up to approximately Week 96
Area Under the Plasma Concentration-Time Curve (AUC0-24h) of Fosigotifator
大体时间:Baseline up to approximately Week 96

AUC0-24h of Fosigotifator

Baseline up to approximately Week 96
Trough Concentration (Ctrough) of Fosigotifator
大体时间:Baseline up to approximately Week 96

Ctrough of Fosigotifator

Baseline up to approximately Week 96
Terminal Elimination Half-Life (t1/2) of Fosigotifator
大体时间:Baseline up to approximately Week 96

t1/2 of Fosigotifator

Baseline up to approximately Week 96

次要结果测量

结果测量
措施说明
大体时间
Incidence of Treatment-Emergent Adverse Events
大体时间:Baseline up to Approximately Week 197

Number of patients with treatment-related adverse events as assessed by CTCAE v4.03

Baseline up to Approximately Week 197
Number of Participants with Change in Vital Signs
大体时间:Baseline up to approximately Week 197

Number of Participants with Change in Vital Signs will be assessed.

Baseline up to approximately Week 197
Number of Participants with Change in ECG
大体时间:Baseline up to approximately Week 197

Number of Participants with Change in ECG will be assessed.

Baseline up to approximately Week 197
Number of Participants with Change in Clinical Laboratory Tests
大体时间:Baseline up to approximately Week 197

Number of participants with change in clinical laboratory tests will be assessed.

Baseline up to approximately Week 197
Change from Baseline in Columbia-Suicide Severity Rating Scale (C-SSRS)
大体时间:Baseline up to approximately Week 197

The C-SSRS is a systematically administered instrument that reports the severity of both suicidal ideation and behavior, with a higher score denoting more severe suicidal ideation and behavior.

Baseline up to approximately Week 197
Number of Participants with Change in Magnetic Resonance Imaging (MRI)
大体时间:Baseline up to approximately Week 192

Change in Brain Magnetic Resonance Imaging (MRI) associated with adverse events.

Baseline up to approximately Week 192

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2023年3月13日

初级完成 (估计的)

2027年11月1日

研究完成 (估计的)

2035年10月1日

研究注册日期

首次提交

2023年2月23日

首先提交符合 QC 标准的

2023年3月3日

首次发布 (实际的)

2023年3月7日

研究记录更新

最后更新发布 (实际的)

2026年10月19日

上次提交的符合 QC 标准的更新

2026年10月16日

最后验证

2026年10月1日

更多信息

与本研究相关的术语

其他研究编号

  • M23-523
  • 2023-505704-30-00 (其他标识符:EU CT)
  • 2023 (美国 NIH 拨款/合同)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

未定

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

在美国制造并从美国出口的产品

是的

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅